In the EMPA-KIDNEY trial, the SGLT2 inhibitor empagliflozin reduced the risk of kidney disease progression in a broad patient population.

中文翻译：

---

阻止肾脏疾病的进展


在 EMPA-KIDNEY 试验中，SGLT2 抑制剂恩格列净降低了广大患者群体肾病进展的风险。